Perceptive Advisors LLC bought a new position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ – Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The fund bought 170,000 shares of the specialty pharmaceutical company’s stock, valued at approximately $28,900,000.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Dimensional Fund Advisors LP grew its stake in Jazz Pharmaceuticals by 11.8% during the 3rd quarter. Dimensional Fund Advisors LP now owns 2,836,652 shares of the specialty pharmaceutical company’s stock worth $373,855,000 after buying an additional 298,815 shares during the last quarter. Capital World Investors grew its stake in Jazz Pharmaceuticals by 4.4% during the 4th quarter. Capital World Investors now owns 2,666,602 shares of the specialty pharmaceutical company’s stock worth $453,322,000 after buying an additional 111,735 shares during the last quarter. Ameriprise Financial Inc. grew its stake in Jazz Pharmaceuticals by 11.4% during the 2nd quarter. Ameriprise Financial Inc. now owns 1,867,399 shares of the specialty pharmaceutical company’s stock worth $198,159,000 after buying an additional 191,637 shares during the last quarter. JPMorgan Chase & Co. grew its stake in Jazz Pharmaceuticals by 8.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,867,159 shares of the specialty pharmaceutical company’s stock worth $246,092,000 after buying an additional 145,865 shares during the last quarter. Finally, Franklin Resources Inc. lifted its position in Jazz Pharmaceuticals by 164.0% during the 4th quarter. Franklin Resources Inc. now owns 1,818,911 shares of the specialty pharmaceutical company’s stock worth $309,215,000 after acquiring an additional 1,129,995 shares during the period. 89.14% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
A number of analysts have commented on the company. Raymond James Financial reaffirmed an “outperform” rating and set a $239.00 price target on shares of Jazz Pharmaceuticals in a research report on Wednesday, May 6th. UBS Group raised Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $188.00 to $307.00 in a research report on Tuesday, May 19th. Morgan Stanley reaffirmed an “overweight” rating and set a $245.00 price target on shares of Jazz Pharmaceuticals in a research report on Thursday, May 7th. TD Cowen lifted their price target on Jazz Pharmaceuticals from $220.00 to $275.00 and gave the stock a “buy” rating in a research report on Wednesday, May 6th. Finally, Piper Sandler lifted their price target on Jazz Pharmaceuticals from $232.00 to $301.00 and gave the stock an “overweight” rating in a research report on Friday, May 22nd. Sixteen analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $246.06.
More Jazz Pharmaceuticals News
Here are the key news stories impacting Jazz Pharmaceuticals this week:
- Positive Sentiment: Jazz announced a major research collaboration and licensing deal with AbCellera to discover and develop next-generation T-cell engaging multispecific antibodies for cancer, including solid tumors. The agreement could be worth up to roughly $820 million to $876 million per drug if milestones are achieved, signaling a potentially meaningful new pipeline opportunity. Article: Jazz Pharma, AbCellera ink antibody deal worth up to $876 million
- Positive Sentiment: Jazz also released extensive late-breaking data at SLEEP 2026 showing real-world benefits of Xywav in narcolepsy and idiopathic hypersomnia, including evidence of improved patient outcomes and possible cardiometabolic benefits linked to reduced sodium exposure. That supports the company’s commercial franchise and may reinforce confidence in a core revenue driver. Article: Jazz Pharmaceuticals Delivers Extensive Late-Breaking Data at SLEEP 2026
- Neutral Sentiment: A director disclosed a planned sale of 1,157 shares under a pre-arranged 10b5-1 trading plan. While insider selling can sometimes attract attention, the small size and scheduled nature make it unlikely to be a major fundamental concern. Article: SEC filing for director sale
Jazz Pharmaceuticals Stock Performance
Shares of JAZZ stock opened at $226.93 on Thursday. The stock has a market cap of $14.26 billion, a PE ratio of -11,340.83, a price-to-earnings-growth ratio of 0.20 and a beta of 0.32. The business has a 50-day simple moving average of $220.08 and a 200-day simple moving average of $189.96. The company has a quick ratio of 1.85, a current ratio of 2.04 and a debt-to-equity ratio of 0.95. Jazz Pharmaceuticals PLC has a 52-week low of $105.00 and a 52-week high of $243.32.
Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) last issued its quarterly earnings data on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share (EPS) for the quarter. The business had revenue of $1.07 billion during the quarter. Jazz Pharmaceuticals had a return on equity of 14.56% and a net margin of 0.66%. On average, equities analysts expect that Jazz Pharmaceuticals PLC will post 22.09 EPS for the current year.
Insiders Place Their Bets
In other news, EVP Neena M. Patil sold 1,200 shares of the business’s stock in a transaction dated Wednesday, June 10th. The stock was sold at an average price of $231.83, for a total value of $278,196.00. Following the completion of the transaction, the executive vice president owned 51,549 shares of the company’s stock, valued at $11,950,604.67. The trade was a 2.27% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Heather Ann Mcsharry sold 2,000 shares of the business’s stock in a transaction dated Friday, May 22nd. The shares were sold at an average price of $241.00, for a total value of $482,000.00. Following the completion of the transaction, the director directly owned 18,449 shares of the company’s stock, valued at approximately $4,446,209. This trade represents a 9.78% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 13,098 shares of company stock worth $2,832,086. 4.10% of the stock is currently owned by company insiders.
Jazz Pharmaceuticals Profile
Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.
Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.
Featured Stories
- Five stocks we like better than Jazz Pharmaceuticals
- Cheap Thrills: Why These 3 Entertainment Stocks Are Soaring
- CoreWeave Insider Sales Look Big, But Should Investors Worry?
- Critical Metals: Sizing Up This Tiny Rare-Earth Stock Making Big Moves
- Meta and Cloud Computing: Real Potential, or a Shot in the Dark?
Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ – Free Report).
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
-limited-logo-1200x675.png){kind=logo}
